VEGF-B Inhibitors
1 drugsAbout VEGF-B
Vascular Endothelial Growth Factor B (VEGF-B) is a protein involved in angiogenesis and vascular permeability. As a member of the VEGF family, it has been implicated in tumor growth and metastasis, making it a target of interest in oncology.
VEGF-B is explored as a therapeutic target to disrupt the blood supply fueling tumor growth. Currently, there is no genetic evidence available linking VEGF-B to specific diseases, highlighting an area for future investigation.
VEGF-B is targeted by one FDA-approved drug, ZALTRAP (a fusion protein), developed by Sanofi for oncology indications. Further research is needed to fully elucidate VEGF-B's role and therapeutic potential.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Wet AMD with only 3 trials.
Top VEGF-B Drugs
Sanofi is the only company with an approved drug targeting VEGF-B.
Limited competition presents an opportunity for new entrants, but also indicates potential challenges.
VEGF-B Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets VEGF-B, using fusion protein modality.
Explore alternative modalities like antibodies or small molecules to diversify the therapeutic approach.
VEGF-B Clinical Trials 296 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 40 | 26 | 7 | 6 | 79% |
| Phase 2 | 92 | 60 | 18 | 14 | 77% |
| Phase 3 | 91 | 56 | 13 | 22 | 81% |
| Phase 4 | 73 | 55 | 9 | 9 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
VEGF-B Drug Approval Timeline (2012 - 2012)
The first and only drug, ZALTRAP, was approved in 2012.
The lack of recent approvals suggests a saturated market or challenges in developing new VEGF-B inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 9 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 211 clinical trials targeting VEGF-B.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities